Immune thrombocytopenia (ITP) is a heterogeneous disease with a varied clinical course, and although clinical guidelines have been recently updated, many unanswered questions remain. Is splenectomy an outdated treatment for ITP? How are thrombopoietin receptor agonists used? How is the patientís quality of life impacted by the disease, treatments, and adverse events? Through a series of presentations and discussions based on questions like these, this symposium is designed to help practitioners provide the best possible care for their patients with ITP.

Accreditation Statement
Hemedicus, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit
Hemedicus designates this live activity for a maximum of 3 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.